Sol-Gel Technologies Ltd.

NASDAQ:SLGL

Biotechnology

Healthcare
$53.36 +1.69%

+$1.19 today

Market cap
$174.70M
Beta
1.13
P/E (TTM)
-194.1
EPS (TTM)
-$0.37
52W Low $6.96High $97.97

Volume 0.03M

Average 0.04M

SLGL Income Before Tax

Profit after all operating and non-operating items but before income tax.

Sol-Gel Technologies Ltd.NASDAQ: SLGL

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$3.73M, compared with -$8.81M a year earlier. Trailing-twelve-month income before tax was -$1.05M.

Context

  • Income before tax amounted to 31.6% of revenue in FY2025, down 60.1 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$3.73M or moves back toward the trailing-twelve-month quarterly average of -$261.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.73M-24.8% QoQ
Last fiscal yearDec 2025
-$6.13M+42.1% YoY
LTMMar 2026
-$1.05M+92.0% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57.7%——
1 year+42.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(6.13M) USD
Year-over-year change
+42.1%

Income Before Tax vs competitors

How SLGL compares with its peers on the latest reported figures

  • SLGL's LTM Mar 2026 income before tax of -$1.05M is the 2nd highest of the 10 companies compared; the peer median is -$24.17M.
  • Its year-over-year change of +92.0% is the 2nd highest of 10, against a peer median of +3.2%.
  • Income before tax amounts to 5.7% of revenue for SLGL, versus a peer median of 302.7%.
SLGL Competitors Peer median
Income Before Tax for SLGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$131.82M +637.8%——
SLGLSol-Gel Technologies Ltd.LTM Mar 2026-$1.05M +92.0%—5.7%
OKYOOKYO Pharma LimitedFY2025-$7.97M +52.6%——
TLSATiziana Life Sciences LtdFY2025-$18.43M -10.1%——
COYACoya Therapeutics, Inc.LTM Mar 2026-$21.12M -18.3%—266.1%
OVIDOvid Therapeutics Inc.LTM Mar 2026-$24.17M +3.2%—339.3%
CLNNClene Inc.LTM Mar 2026-$33.51M -15.3%—25009.7%
MGNXMacroGenics, Inc.LTM Mar 2026-$71.03M -29.5%—45.2%
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$113.22M +48.4%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$123.57M +44.9%——
Peer median (excluding SLGL) -$24.17M+3.2%—302.7%

Competitors are the stored peer set for SLGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue31.27M3.88M1.55M11.54M19.39M
Cost of Revenue20.38M12.68M342K233K109K
Gross Profit10.89M(8.8M)(21.99M)11.31M19.39M
Gross Margin34.8%-226.6%-1414.9%98.0%100.0%
Research & Development20.38M12.68M23.54M17.8M22.8M
Selling, General & Admin8.45M7.45M7.37M5.75M4.18M
Operating Expenses7.93M7.45M7.32M23.32M26.93M
Depreciation & Amortization880K562K342K233K109K
EBITDA3.84M(15.68M)(28.96M)(10.35M)(7.43M)
EBITDA Margin12.3%-403.9%-1863.8%-89.7%-38.3%
Operating Income2.96M(16.24M)(29.31M)(12.01M)(7.54M)
Operating Margin9.5%-418.3%-1885.8%-104.1%-38.9%
Interest Income257K1.32M2.07M1.43M1.41M
Interest Expense00000
Other Income / Expenses257K1.32M2.07M1.43M1.41M
Income Before Tax3.22M(14.92M)(27.24M)(10.58M)(6.13M)
Pre-Tax Margin10.3%-384.3%-1752.8%-91.7%-31.6%
Income Tax Expense00000
Net Income3.22M(14.92M)(27.24M)(10.58M)(6.13M)
Net Margin10.3%-384.3%-1752.8%-91.7%-31.6%
EPS (Basic)1.40(0.65)(1.01)(0.38)(2.20)
EPS (Diluted)0.14(0.65)(1.01)(0.38)(2.20)
Weighted Avg Shares23.06M23.13M27.09M27.86M2.79M
Weighted Avg Shares (Diluted)23.57M23.13M27.09M27.86M2.79M

Sol-Gel Technologies Ltd.

NASDAQ:SLGL

Intrinsic Alpha fair value

Locked

Current Price

$53.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.